🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Olodaterol (BI1744) Low

Found 16 matching trials

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

PHASE3

The primary objective of this study is to assess the long-term efficacy and...

Status

Completed

Location

1222.14.5004 Boehringer Ingelheim Investigational Site

Start Date

2009-01

Trial ID

NCT00796653

Treatments Being Tested

Olodaterol (BI 1744)Olodaterol (BI 1744)Formoterol Placebo

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The primary objective of this study is to determine the optimum dose(s) of ...

Status

Completed

Location

1237.9.00152 Boehringer Ingelheim Investigational Site

Start Date

2008-07

Trial ID

NCT00720499

Treatments Being Tested

BI 1744 CL plus tiotropium bromide Respimat® Inhaler

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

PHASE3

The study is intended to characterize the lung function profile of BI1744 i...

Status

Completed

Location

1222.25.25009 Boehringer Ingelheim Investigational Site

Start Date

2009-06

Trial ID

NCT00932646

Treatments Being Tested

BI 1744 (Olodaterol) Low Dose BI 1744 (Olodaterol) Medium Dose Placebo Foradil

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

PHASE2

The primary objective of this study is to determine the optimum dose(s) of ...

Status

Completed

Location

1237.4.0118 Boehringer Ingelheim Investigational Site

Start Date

2008-06

Trial ID

NCT00696020

Treatments Being Tested

BI 1744 CL/tiotropium bromide fixed dose combination tiotropium bromide Respimat® Inhaler

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

PHASE3

The study is intended to characterize the lung function profile of BI1744 i...

Status

Completed

Location

1222.39.32003 Boehringer Ingelheim Investigational Site

Start Date

2010-01

Trial ID

NCT01040689

Treatments Being Tested

Olodaterol (BI1744) Low Placebo (for olodaterol BI1744)Placebo (for Tiotropium)Olodaterol (BI1744) High Tiotropium 18 mcg

Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma

PHASE2

The primary objective of this study is to assess the efficacy (bronchoprote...

Status

Completed

Location

1222.4.103 UBC - Respiratory Medicine

Start Date

2006-01

Trial ID

NCT00928668

Treatments Being Tested

Placebo Olodaterol (BI1744CL)Olodaterol (BI1744CL)Olodaterol (BI1744CL)Olodaterol (BI1744CL)

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

PHASE3

The primary objective of this study is to assess the long-term efficacy and...

Status

Completed

Location

1222.13.2401 Boehringer Ingelheim Investigational Site

Start Date

2009-02

Trial ID

NCT00793624

Treatments Being Tested

Olodaterol (BI 1744)Olodaterol (BI 1744)Formoterol Placebo Placebo

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

PHASE3

To compare the effects of BI 1744 CL versus placebo on exercise tolerance a...

Status

Completed

Location

1222.37.6171 Boehringer Ingelheim Investigational Site

Start Date

2010-01

Trial ID

NCT01040130

Treatments Being Tested

Olodaterol (BI 1744)Olodaterol (BI 1744)Placebo Olodaterol (BI 1744)Olodaterol (BI 1744) Placebo

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

PHASE1

The main objective of this study was to investigate the influence of mild a...

Status

Completed

Location

Multiple Locations

Start Date

2009-07

Trial ID

NCT02171832

Treatments Being Tested

BI 1744 CL, low dose BI 1744 CL, high dose

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The primary objective of this study is to determine the optimum once daily ...

Status

Completed

Location

1237.18.02004 Boehringer Ingelheim Investigational Site

Start Date

2010-01

Trial ID

NCT01040403

Treatments Being Tested

olodaterol (BI 1744) low low tiotropium bromide olodaterol (BI 1744) high medium tiotropium bromide high tiotropium bromide Placebo Respimat

Previous Next